Next Article in Journal
Comparative and Expression Analysis of Ubiquitin Conjugating Domain-Containing Genes in Two Pyrus Species
Next Article in Special Issue
The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview
Previous Article in Journal
Cell Signaling in Neuronal Stem Cells
Previous Article in Special Issue
Receptor Tyrosine Kinase Ubiquitination and De-Ubiquitination in Signal Transduction and Receptor Trafficking
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessFeature PaperReview
Cells 2018, 7(7), 76; https://doi.org/10.3390/cells7070076

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

1
Department of Medical, Surgical & Health Sciences, University of Trieste, Cattinara Teaching Hospital, 34149 Trieste, Italy
2
Department of Medical, Surgery & Health Sciences, University of Trieste, 34129 Trieste, Italy
3
Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), 85028 Rionero, Italy
4
Department of Medical, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy; Breast Cancer Unit and Translational Research Unit, ASST Cremona, Viale Concordia 1, C.A.P. 26100 Cremona, Italy
*
Authors to whom correspondence should be addressed.
Received: 5 June 2018 / Revised: 30 June 2018 / Accepted: 11 July 2018 / Published: 15 July 2018
(This article belongs to the Special Issue Receptor Tyrosine Kinases in Health and Disease)
Full-Text   |   PDF [808 KB, uploaded 15 July 2018]   |  

Abstract

Breast cancer (BC) is the most common malignancy and second only to lung cancer in terms of mortality in women. Despite the incredible progress made in this field, metastatic breast cancer has a poor prognosis. In an era of personalized medicine, there is an urgent need for better knowledge of the biology leading to the disease, which can lead to the design of increasingly accurate drugs against patients’ specific molecular aberrations. Among one of the actionable targets is the fibroblast growth factor receptor (FGFR) pathway, triggered by specific ligands. The Fibroblast Growth Factor Receptors/Fibroblast Growth Factors (FGFRs/FGFs) axis offers interesting molecular targets to be pursued in clinical development. This mini-review will focus on the current knowledge of FGFR mutations, which lead to tumor formation and summarizes the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of BC. View Full-Text
Keywords: fibroblast growth factor; fibroblast growth factor receptor; targeted treatments; breast cancer fibroblast growth factor; fibroblast growth factor receptor; targeted treatments; breast cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sobhani, N.; Ianza, A.; D’Angelo, A.; Roviello, G.; Giudici, F.; Bortul, M.; Zanconati, F.; Bottin, C.; Generali, D. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. Cells 2018, 7, 76.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top